Literature DB >> 27670678

Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.

Alberto Hernández-Tejedor1, Carmen Débora Merino-Vega2, Alfredo Martín-Vivas2, Rafael Ruiz de Luna-González2, Alberto Delgado-Iribarren3, Ángeles Gabán-Díez2, Ignacio Temprano-Gómez2, Natalia de la Calle-Pedrosa2, Ana Isabel González-Jiménez2, Alejandro Algora-Weber2.   

Abstract

INTRODUCTION: Ceftolozane/tazobactam is a novel antibiotic approved for the treatment of complicated intra-abdominal and complicated urinary tract infections. CASE DESCRIPTION: We describe the use of off-label ceftolozane/tazobactam in the management of a multidrug-resistant Pseudomonas aeruginosa bacteremia that was already being treated with colistin and amikacin, the only active antibiotics according to the antibiogram.

Entities:  

Keywords:  Bacteremia; Ceftolozane/tazobactam; Multidrug-resistant Pseudomonas aeruginosa

Mesh：

Substances：

Year:  2016        PMID： 27670678     DOI： 10.1007/s15010-016-0944-5

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  4 in total

1.  Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.

Authors:  Michael S Gelfand; Kerry O Cleveland
Journal:  Clin Infect Dis       Date:  2015-05-28       Impact factor: 9.079

2.  Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy.

Authors:  Derek N Bremmer; David P Nicolau; Pam Burcham; Anil Chunduri; Ganesh Shidham; Karri A Bauer
Journal:  Pharmacotherapy       Date:  2016-05-02       Impact factor: 4.705

3.  Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates.

Authors:  David R Snydman; Laura A McDermott; Nilda V Jacobus
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

4.  Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.

Authors:  Alan J Xiao; Benjamin W Miller; Jennifer A Huntington; David P Nicolau
Journal:  J Clin Pharmacol       Date:  2015-08-25       Impact factor: 3.126
  4 in total
  10 in total

1.  Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections.

Authors:  Laura Escolà-Vergé; Carles Pigrau; Ibai Los-Arcos; Ángel Arévalo; Belen Viñado; David Campany; Nieves Larrosa; Xavier Nuvials; Ricard Ferrer; Oscar Len; Benito Almirante
Journal:  Infection       Date:  2018-03-28       Impact factor: 3.553

Review 2.  Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?

Authors:  Lynn Nguyen; Joshua Garcia; Katherine Gruenberg; Conan MacDougall
Journal:  Curr Infect Dis Rep       Date:  2018-06-06       Impact factor: 3.725

3.  Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections.

Authors:  Juan José Castón; Álvaro De la Torre; Isabel Ruiz-Camps; María Luisa Sorlí; Vicente Torres; Julián Torre-Cisneros
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

Review 4.  Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections.

Authors:  Aaron Matlock; Joshua Allan Garcia; Kayvan Moussavi; Brit Long; Stephen Yuan-Tung Liang
Journal:  Intern Emerg Med       Date:  2021-05-06       Impact factor: 5.472

5.  Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.

Authors:  David M Livermore; Shazad Mushtaq; Daniele Meunier; Katie L Hopkins; Robert Hill; Rachael Adkin; Aiysha Chaudhry; Rachel Pike; Peter Staves; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

6.  Real-world use of ceftolozane/tazobactam: a systematic literature review.

Authors:  Laura Puzniak; Ryan Dillon; Thomas Palmer; Hannah Collings; Ashley Enstone
Journal:  Antimicrob Resist Infect Control       Date:  2021-04-08       Impact factor: 4.887

Review 7.  Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians.

Authors:  Luigi Principe; Tommaso Lupia; Lilia Andriani; Floriana Campanile; Davide Carcione; Silvia Corcione; Francesco Giuseppe De Rosa; Roberto Luzzati; Giacomo Stroffolini; Marina Steyde; Giuliana Decorti; Stefano Di Bella
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-12

Review 8.  Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections.

Authors:  Laura Puzniak; Ryan Dillon; Thomas Palmer; Hannah Collings; Ashley Enstone
Journal:  Infect Dis Ther       Date:  2021-07-18

Review 9.  Ceftolozane/Tazobactam for Resistant Drugs Pseudomonas aeruginosa Respiratory Infections: A Systematic Literature Review of the Real-World Evidence.

Authors:  Luca Gregorio Giaccari; Maria Caterina Pace; Maria Beatrice Passavanti; Francesca Gargano; Caterina Aurilio; Pasquale Sansone
Journal:  Life (Basel)       Date:  2021-05-24

10.  Postoperative soft-tissue infection due to multidrug-resistant Pseudomonas aeruginosa: usefulness of ceftolozane-tazobactam.

Authors:  J Monterrubio-Villar; S Rodríguez-Garrido; J D Jiménez-Delgado
Journal:  Rev Esp Quimioter       Date:  2018-07-09       Impact factor: 1.553
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.